Published on 09/12/2025

Designing SUS Leachables Studies for Real-Use Conditions

In the pharmaceutical industry, ensuring the safety and efficacy of products is paramount. One of the pressing concerns in the development and validation of single-use systems (SUS) is the assessment of extractables and leachables (E&L). This article aims to provide a comprehensive step-by-step tutorial on designing E&L studies for real-use conditions, particularly focusing on filters and gamma-irradiated products. Leveraging guidelines such as USP chapter on container closure integrity (CCI) and regulatory expectations from the FDA and EMA, this guide will outline the critical components involved in E&L risk assessment, analytical evaluation threshold (AET), dose-based threshold (DBT) calculations, and the principles established by the PQRI guideline.

Step 1: Understanding Extractables and Leachables

Extractables and leachables are two terms that describe the substances that may migrate from packaging or delivery devices into the drug product. Extractables are compounds that can be removed from the material under aggressive testing conditions, typically using solvents, elevated temperature, or other means. Leachables, on the other hand, are those substances that migrate into the drug product under actual storage and use conditions. Understanding the difference is crucial for designing effective studies.

In the context of pharmaceutical validation, the focus on E&L arises due to the impact that these substances can have on product safety, efficacy, and patient health. Regulations from the FDA and EMA outline the necessary compliance with good manufacturing practices (GMP) to ensure that these risks are adequately managed.

Regulatory Framework and Guidelines

• The FDA has published guidelines that emphasize E&L assessments.
• EU GMP Annex 1 includes directives about E&L in the context of sterile products.
• The Pharmaceutical Quality Research Institute (PQRI) offers guidelines on E&L studies, particularly for leachables testing.

Familiarity with these regulations is essential for ensuring compliance and effective study design.

Step 2: Identifying Real-Use Conditions

The next step involves determining the real-use conditions under which the drug product will be handled. This requires understanding every step in the product lifecycle, from manufacturing to patient administration. Considerations should include:

• Storage Conditions: Temperature, humidity, and light exposure.
• Duration of Use: The time the drug product will be in contact with the storage material, such as filters and bags.
• Method of Use: How the product is administered, which will influence leachable quantities due to mechanical or physical forces.

Documenting these real-use conditions will inform the parameters and criteria for the E&L studies, ensuring they are relevant to actual scenarios encountered in practice.

Adapting to the Drug Formulation

Consider how the drug formulation itself might react with different materials. For instance, pH level, concentration, and the presence of other excipients can affect the leaching potential. A thorough understanding of the drug formulation will help in selecting appropriate materials for testing.

Step 3: Material Selection and Sample Preparation

Once real-use conditions are established, the next step focuses on the selection of materials (e.g., filters, bags) for the study. Here, the primary objective is to identify materials that are representative of what will be used in the actual process. Selection criteria should include:

• Material Compatibility: Assess if the materials intended for the study can potentially interact with the drug formulation.
• Manufacturing Differences: Differences in manufacturing processes can introduce variability. Choose materials that reflect the final product.
• Historical Data: Previous studies on the materials can provide insights into potential E&L issues.

Proper sample preparation is vital; sample sizes must be appropriate for the testing methods employed. Follow the guidelines stipulated by the [USP](https://www.usp.org/) for sample preparation specific to E&L studies.

Step 4: Analytical Method Development

The subsequent step involves developing or selecting robust analytical methods for detecting and quantifying E&L. Analytical methods may include a variety of techniques, such as:

• Gas Chromatography-Mass Spectrometry (GC-MS): Widely used for volatile compounds.
• High-Performance Liquid Chromatography (HPLC): Effective for less volatile and more polar substances.
• Liquid Chromatography-Mass Spectrometry (LC-MS): Ideal for complex mixtures.

Ensure analytical methods chosen demonstrate specificity, sensitivity, and reproducibility, which are essential for regulatory compliance. Calibration using known standards is crucial to ensure data reliability.

Developing Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

Setting the Analytical Evaluation Threshold (AET) is critical for distinguishing between relevant and irrelevant leachables. The AET is grounded in the safety assessment of the drug product and is determined based on factors such as:

1. The toxicological profile of leachables.
2. The daily dose of the drug product.
3. The volume of the product administered to patients.

The Dose-Based Threshold (DBT) is calculated similarly and provides a guideline to evaluate healthcare products based on dosing regimens. Both thresholds must align with regulatory expectations as outlined in the PQRI guideline, ensuring that the E&L profile of the drug product is acceptable under normal usage conditions.

Step 5: Conducting the E&L Study

With methods established, practical work can finally begin. Conduct the E&L study under the conditions identified in step two. This includes:

• Utilizing the appropriate solvents and temperatures to elicit maximum extraction of potential leachables.
• Documenting every stage of the study process to assure reproducibility and traceability.
• Conducting testing in a controlled environment, adhering to cGMP requirements.

Regularly consult with QA personnel to confirm that procedures are in compliance with both internal standards and regulatory guidelines. Capture all data meticulously, as this will be critical for the assessment phase.

Step 6: Data Analysis and Interpretation

Post-study analysis involves evaluating the gathered data against the predetermined thresholds (AET and DBT). The following aspects should be reviewed:

• Identification of Leachables: Confirm the identity and concentration of leachables against established standards.
• Comparative Analysis: Compare results to AET and DBT to assess the overall burden of leachables on the drug product.
• Regulatory Reporting: Prepare documentation required for submission and regulatory review in compliance with FDA and EMA standards.

Document any findings in a comprehensive report, detailing methodologies, results, interpretations, and conclusions drawn from the data analysis.

Step 7: Container Closure Integrity (CCI) Testing

Alongside E&L studies, Container Closure Integrity (CCI) testing must be conducted to ensure packaging maintains its barrier properties throughout the product’s shelf life. CCI testing procedures often include:

• Seal Integrity Testing: Techniques such as vacuum decay or dye immersion tests guarantee that the container effectively protects the product.
• Real-Time Analysis: Continuous monitoring during the lifecycle of drug products ensures ongoing compliance with integrity expectations.
• Statistical Analysis: Apply statistical tools to predict the lifespan and failure rates of container systems based on integrity data.

Adhering to the USP guidelines for CCI ensures that the container system used is suitable for the intended drug product and use conditions.

Step 8: Final Reporting and Decision Making

The final step is compiling all data and insights garnered from the E&L study and CCI testing into a comprehensive report. This report serves as a critical document for regulatory submissions and should include:

• Executive Summary: Background, purpose, and high-level findings from the studies.
• Detailed Methodologies: Description of methods used, including AET and DBT calculations.
• Discussion of Results: Comprehensive analysis of leachables identified, their significance, and relevance to the drug product.
• Regulatory Compliance: Summary of how studies meet FDA, EU, and other relevant standards.

Utilize this report as a basis for informed decision-making regarding the use of single-use systems in drug manufacturing. Engage in discussions with stakeholders, ensuring that risks are clearly communicated and understood.

Conclusion

Designing E&L studies for real-use conditions is a critical part of the pharmaceutical validation process. By carefully considering real-use scenarios, selecting appropriate materials and methodologies, and rigorously analyzing the data, pharmaceutical companies can provide assurance of E&L safety and compliance. Following regulatory guidelines such as those from the FDA and EMA, as well as the PQRI guidelines, assists professionals in navigating the complexities and nuances of E&L assessments in the development of single-use systems.